GlassScriptPhysician profile
Amber N Thorne
NPI 1427385376
$1,516.59
in general payments reported to CMS, 2019-2025
22 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.94 · 2022: $36.77 · 2023: $283 · 2024: $694 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $344.65 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $214.14 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $151.49 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $99.73 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $96.27 | 2024-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $88.51 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $87.30 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.52 | 2023-2024 | Caplyta |
| Janssen Biotech, INC. | $44.94 | 2021 | |
| Alkermes, INC. | $42.75 | 2024 | Aristada, Lybalvi |
| Novo Nordisk INC | $36.60 | 2022-2024 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $33.53 | 2024 | Uzedy, Austedo Xr |
| Indivior INC. | $24.87 | 2023 | Perseris |
| Inspire Medical Systems, INC. | $23.12 | 2023 | Inspire |
| Neurocrine Biosciences, INC. | $23.06 | 2024 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $22.16 | 2024 | Subvenite |
| Astrazeneca Pharmaceuticals LP | $17.90 | 2025 | Breztri |
| Amgen INC. | $17.82 | 2025 | Repatha, Otezla |
| Ardelyx, INC. | $16.92 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $16.58 | 2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $15.73 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Thorne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.